Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C112
- Development stage
- Preclinical
- Lead developer
- Vicore Pharma
- Modality
- Small Molecules
01
Overview
C112 is a highly potent and selective next-generation angiotensin II type 2 receptor (AT2R) agonist (ATRAG) developed by Vicore Pharma. It is designed to promote anti-inflammatory, anti-fibrotic, and vasodilatory pathways. In ex vivo human fibrotic kidney slices, C112 has demonstrated superior anti-fibrotic and fibrolytic properties compared to buloxibutid (C21), significantly reducing profibrotic mediators such as collagen type I alpha-1 (COL1A1) and transforming growth factor-beta 1 (TGF-beta 1) while increasing the fibrolytic protease matrix metalloproteinase-1 (MMP-1). C112 is currently in preclinical development for the treatment of chronic kidney disease and renal fibrosis.
02
Targets
AGTR2 (AT2)
Beyond the preview
Go deeper on C112.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C112.